Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-14-034322
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-05-15 17:45:28
Reporting Period:
2014-05-13
Filing Date:
2014-05-15
Accepted Time:
2014-05-15 17:45:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1423824 Alder Biopharmaceuticals Inc ALDR Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1255743 J James Bochnowski C/o Delphi Ventures
3000 Sand Hill Rd., Bldg. 1, Suite 135
Menlo Park CA 94025
No No Yes No
1270734 Deepika Pakianathan C/o Delphi Ventures
3000 Sand Hill Rd., Bldg 1, Suite 135
Menlo Park CA 94025
Yes No Yes No
1270735 A Douglas Roeder C/o Delphi Ventures
3000 Sand Hill Rd., Bldg., Suite 135
Menlo Park CA 94025
No No Yes No
1271389 L David Douglass C/o Delphi Ventures
3000 Sand Hill Rd., Bldg. 1, Suite 135
Menlo Park CA 94025
No No Yes No
1336922 P L Vii Ventures Delphi 3000 Sand Hill Road
Building 1, Suite 135
Menlo Park CA 94025
No No Yes No
1346198 Delphi Bioinvestments Vii Lp 3000 Sand Hill Road
Building 1, Suite 135
Menlo Park CA 94025
No No Yes No
1457493 Delphi Management Partners Vii, L.l.c. C/o Delphi Ventures
3000 Sand Hill Rd., Bldg. 1, Suite 135
Menlo Park CA 94025
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-05-13 2,463,894 $0.00 2,463,894 No 4 C Indirect By Delphi Ventures VII, L.P.
Common Stock Acquisiton 2014-05-13 24,638 $0.00 2,488,532 No 4 C Indirect By Delphi BioInvestments VII, L.P.
Common Stock Acquisiton 2014-05-13 346,535 $10.00 2,835,067 No 4 P Indirect By Delphi Ventures VII, L.P.
Common Stock Acquisiton 2014-05-13 3,465 $10.00 2,838,532 No 4 P Indirect By Delphi BioInvestments VII, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect By Delphi Ventures VII, L.P.
No 4 C Indirect By Delphi BioInvestments VII, L.P.
No 4 P Indirect By Delphi Ventures VII, L.P.
No 4 P Indirect By Delphi BioInvestments VII, L.P.
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series C Preferred Stock Disposition 2014-05-13 2,083,541 $0.00 2,083,541 $0.00
Common Stock Series D Preferred Stock Disposition 2014-05-13 380,353 $0.00 380,353 $0.00
Common Stock Series C Preferred Stock Disposition 2014-05-13 20,835 $0.00 20,835 $0.00
Common Stock Series D Preferred Stock Disposition 2014-05-13 3,803 $0.00 3,803 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. The preferred stock converted into common stock on a 1-for-1 basis upon the closing of the issuer's initial public offering and had no expiration date.
  2. The reported securities are directly owned by Delphi Ventures VII, L.P. ("DV VII). DMP VII is the general partner of DV VII and may be deemed to have sole voting and dispositive power over the securities held by DV VII. Douglas A. Roeder, James J. Bochnowski, David L. Douglass and Deepika R. Pakianathan, Ph.D. are the managing members of DMP VII and may be deemed to share voting and dispositive power over the securities held by DV VII. Such persons and entities disclaim beneficial ownership of the securities held by DV VII, except to the extent of any pecuniary interest therein.
  3. The reported securities are directly owned by Delphi BioInvestments VII, L.P. ("DBI VII). DMP VII is the general partner of DBI VII and may be deemed to have sole voting and dispositive power over the securities held by DBI VII. Douglas A. Roeder, James J. Bochnowski, David L. Douglass and Deepika R. Pakianathan, Ph.D. are the managing members of DMP VII and may be deemed to share voting and dispositive power over the securities held by DBI VII. Such persons and entities disclaim beneficial ownership of the securities held by DBI VII, except to the extent of any pecuniary interest therein.